Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch reduction in patients treated with roflumilast foam, 0.3%. Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo.
This article was originally published on MedicalXpress.com